The anti-diabetic drug metformin, which has an excellent safety profile and is in a clinical trial for IDH1 mutant solid tumours69, inhibits complex I and may be suitable for maintenance therapy aimed at targeting residual preleukemic clones in IDH1-mutant AML patients in remission. Here, IDH1 is linked to acute myeloid leukemia.